ArticleJournal of surgical oncology2025
Understanding Trends in Incidence and Management of Pregnancy-Associated Breast Cancer in a National Sample Using Claims Data.
Article in Journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pregnancy-Associated Breast Cancer: A Trimester and Subtype Based Clinical Decision Framework for the Surgeon and Surgical Trainee.Annals of surgical oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
objectivesBreast cancer incidence in young women is increasing globally. Here, we examine trends in incidence, management, and reconstruction for pregnancy-associated breast cancer (PABC) in women 18-45.
methodsFemales aged 18-45 with breast cancer between 2007 and 2021 were identified in the Merative MarketScan Commercial and Multi-State Medicaid Databases. We analyzed trends in incidence of PABC, treatments, and latency to treatments for PABC versus non-PABC.
resultsA total of 1189 patients with PABC and 36 683 with non-PABC were included. Over the study period, the proportion of breast cancer cases classified as PABC increased (2.36% of cases from 2007 to 2009, to 3.94% from 2019 to 2021; p < 0.001). Patients with PABC experienced higher rates of neoadjuvant chemotherapy, mastectomy, trastuzumab, and ovarian suppression therapy than patients with non-PABC, and lower rates of adjuvant radiation and breast conserving surgery (p ≤ 0.001). PABC status did not independently predict increased latency from diagnosis to tumor resection surgery when controlling for receipt of neoadjuvant chemotherapy (p = 0.154). Patients with PABC experienced comparable rates of delayed or immediate implant and autologous reconstruction as patients with non-PABC, but experienced increased latency to delayed implant reconstruction (p < 0.001).
conclusionsPABC rates are increasing among women 45 and younger. Patients with PABC experience differences in types of medical/surgical treatments received and timing of post-mastectomy reconstruction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.